---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-044244"
form_type: "8-K"
ticker: null
cik: "0001845459"
company_name: "NKGen Biotech, Inc."
filed_at: "2024-04-05T23:59:59+00:00"
generated_at: "2026-06-04T01:57:23.875432+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NKGen Biotech issues $550K in convertible promissory notes and warrants

## Summary
- Issued 12% promissory notes totaling $550K principal ($500K net) to AJB Capital and Sandia Investment Management.
- Notes mature April 1, 2025, convertible into common stock at $2.00 per share.
- Also issued warrants to purchase up to 550,000 shares at $2.00 per share for five years.
- Proceeds provide working capital; notes include original issue discount and default interest provisions.

## SEC filing metadata
- accession: 0001104659-24-044244
- form_type: 8-K
- cik: 0001845459
- company_name: NKGen Biotech, Inc.
- filed_at: 2024-04-05T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845459/000110465924044244/0001104659-24-044244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845459/000110465924044244/tm2411210d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-044244
- JSON: https://secwatch.observer/filing/0001104659-24-044244.json
- Plain text: https://secwatch.observer/filing/0001104659-24-044244.txt

## Key facts
- Material Agreements
  NKGen Biotech, Inc. entered into AJB Purchase Agreement with AJB Capital Investments LLC (effective 2024-04-01).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: AJB Capital Investments LLC
  - Effective: 2024-04-01
  source text: On April 1, 2024, NKGen Biotech, Inc. (the “ Company ”) issued a 12% promissory note (the “ AJB Note ”) in the principal amount of $330,000, pursuant to a Securities Purchase Agreement (the “ AJB Purchase Agreement ”), by and between the Company and AJB Capital Investments LLC (“ AJB ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000110465924044244/0001104659-24-044244-index.htm
- Material Agreements
  NKGen Biotech, Inc. entered into Sandia Purchase Agreement with Sandia Investment Management LP on behalf of Diametric True Alpha Market Neutral Master Fund LP and Diametric True Alpha Enhanced Market Neutral Master Fund (effective 2024-04-01).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Sandia Investment Management LP on behalf of Diametric True Alpha Market Neutral Master Fund LP and Diametric True Alpha Enhanced Market Neutral Master Fund
  - Effective: 2024-04-01
  source text: On April 1, 2024, the Company issued a 12% promissory note (the “ Sandia Note ”) in the principal amount of $220,000, pursuant to a Securities Purchase Agreement (the “ Sandia Purchase Agreement ”), by and between Sandia Investment Management LP on behalf of Diametric True Alpha Market Neutral Master Fund LP and Diametric True Alpha Enhanced Market Neutral Master Fund (collectively, “ Sandia ”) and the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000110465924044244/0001104659-24-044244-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.